Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer

Czarnecka,Anna  M.; Solarek,Wojciech; Kornakiewicz,Anna; Szczylik,Cezary

doi:10.3892/or.2015.4514

Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer

Authors:
- Anna M. Czarnecka
- Wojciech Solarek
- Anna Kornakiewicz
- Cezary Szczylik
View Affiliations

Affiliations: Laboratory of Molecular Oncology, Department of Oncology, Military Institute of Medicine, 04-141 Warsaw, Poland
Published online on: December 24, 2015 https://doi.org/10.3892/or.2015.4514
Pages: 1433-1442

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

This study was designed to analyze the impact of multi-targeted tyrosine kinase inhibitors on the cancer stem cell subpopulation in renal cell cancer. The second objective was to evaluate the effect of tumor growth inhibition related to a tumor niche factor - oxygen deprivation - as hypoxia develops along with the anti-angiogenic activity of tyrosine kinase inhibitors in renal tumors. Cells were treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, in 2D and 3D culture conditions. Cell proliferation along with drug toxicity were evaluated. It was shown that the proliferation rate of cancer stem cells was decreased by the tyrosine kinase inhibitors. The efficacy of the growth inhibition was limited by hypoxic conditions and 3D intratumoral cell-cell interactions. We conclude that understanding the complex molecular interaction feedback loops between differentiated cancer cells, cancer stem cells and the tumor microenvironment in 3D culture should aid the identification of novel treatment targets and to evalute the efficacy of renal cancer therapies. Cell-cell interaction may represent a critical microenvironmental factor regulating cancer stem cell self-renewal potential, enhancing the stem cell phenotype and limiting drug toxicity. At the same time the role of hypoxia in renal cancer stem cell biology is also significant.

View Figures

View References

1	Buczek M, Escudier B, Bartnik E, Szczylik C and Czarnecka A: Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: From the patient's bed to molecular mechanisms. Biochim Biophys Acta. 1845:31–41. 2014.
2	Młot B, Szczylik C and Rzepecki P: Seeking new prognostic and predictive factors in patients with metastatic renal cell carcinoma - hypoxia-induced factors. Contemp Oncol (Pozn). 16:250–253. 2012.
3	Bielecka ZF, Czarnecka AM and Szczylik C: Genomic analysis as the first step toward personalized treatment in renal cell carcinoma. Front Oncol. 4:1942014. View Article : Google Scholar : PubMed/NCBI
4	Porta C, Bellmunt J, Eisen T, Szczylik C and Mulders P: Treating the individual: The need for a patient-focused approach to the management of renal cell carcinoma. Cancer Treat Rev. 36:16–23. 2010. View Article : Google Scholar
5	Escudier B, Szczylik C, Porta C and Gore M: Treatment selection in metastatic renal cell carcinoma: Expert consensus. Nat Rev Clin Oncol. 9:327–337. 2012. View Article : Google Scholar : PubMed/NCBI
6	Ning X, Shu J, Du Y, Ben Q and Li Z: Therapeutic strategies targeting cancer stem cells. Cancer Biol Ther. 14:295–303. 2013. View Article : Google Scholar : PubMed/NCBI
7	Chow EK: Implication of cancer stem cells in cancer drug development and drug delivery. J Lab Autom. 18:6–11. 2013. View Article : Google Scholar
8	Matak D, Szymanski L, Szczylik C, Sledziewski R, Lian F, Bartnik E, Sobocinska A and Czarnecka AM: Biology of renal tumour cancer stem cells applied in medicine. Contemp Oncol (Pozn). 19:A44–A51. 2015.
9	Czarnecka AM and Szczylik C: Renal cell carcinoma cancer stem cells as therapeutic targets. Curr Signal Transduct Ther. 8:203–209. 2013. View Article : Google Scholar
10	Roskoski R Jr: Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor. Biochem Biophys Res Commun. 356:323–328. 2007. View Article : Google Scholar : PubMed/NCBI
11	Huang D, Ding Y, Li Y, Luo WM, Zhang ZF, Snider J, Vandenbeldt K, Qian CN and Teh BT: Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Cancer Res. 70:1053–1062. 2010. View Article : Google Scholar : PubMed/NCBI
12	Padhye SS, Guin S, Yao HP, Zhou YQ, Zhang R and Wang MH: Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics. Mol Pharm. 8:2310–2319. 2011. View Article : Google Scholar : PubMed/NCBI
13	Diaz R, Nguewa PA, Redrado M, Manrique I and Calvo A: Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells. Prostate. 75:1137–1149. 2015. View Article : Google Scholar : PubMed/NCBI
14	Varna M, Gapihan G, Feugeas JP, Ratajczak P, Tan S, Ferreira I, Leboeuf C, Setterblad N, Duval A, Verine J, et al: Stem cells increase in numbers in perinecrotic areas in human renal cancer. Clin Cancer Res. 21:916–924. 2015. View Article : Google Scholar
15	Adnane L, Trail PA, Taylor I and Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407:597–612. 2006. View Article : Google Scholar : PubMed/NCBI
16	Xin HW, Ambe CM, Hari DM, Wiegand GW, Miller TC, Chen JQ, Anderson AJ, Ray S, Mullinax JE, Koizumi T, et al: Label-retaining liver cancer cells are relatively resistant to sorafenib. Gut. 62:1777–1786. 2013. View Article : Google Scholar : PubMed/NCBI
17	Chow AK, Ng L, Lam CS, Wong SK, Wan TM, Cheng NS, Yau TC, Poon RT and Pang RW: The enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 8:e786752013. View Article : Google Scholar : PubMed/NCBI
18	Hashimoto N, Tsunedomi R, Yoshimura K, Watanabe Y, Hazama S and Oka M: Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer. 14:7222014. View Article : Google Scholar : PubMed/NCBI
19	Yamada T, Abei M, Danjoh I, Shirota R, Yamashita T, Hyodo I and Nakamura Y: Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib. BMC Cancer. 15:2602015. View Article : Google Scholar : PubMed/NCBI
20	Shan J, Shen J, Liu L, Xia F, Xu C, Duan G, Xu Y, Ma Q, Yang Z, Zhang Q, et al: Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology. 56:1004–1014. 2012. View Article : Google Scholar : PubMed/NCBI
21	Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT and Gedaly R: Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res. 34:1709–1713. 2014.PubMed/NCBI
22	Gedaly R, Galuppo R, Musgrave Y, Angulo P, Hundley J, Shah M, Daily MF, Chen C, Cohen DA, Spear BT, et al: PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation. J Surg Res. 185:225–230. 2013. View Article : Google Scholar : PubMed/NCBI
23	Rausch V, Liu L, Kallifatidis G, Baumann B, Mattern J, Gladkich J, Wirth T, Schemmer P, Büchler MW, Zöller M, et al: Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics. Cancer Res. 70:5004–5013. 2010. View Article : Google Scholar : PubMed/NCBI
24	Lee JH, Shim JW, Choi YJ, Heo K and Yang K: The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression. Oncol Rep. 29:917–924. 2013.PubMed/NCBI
25	Carra E, Barbieri F, Marubbi D, Pattarozzi A, Favoni RE, Florio T and Daga A: Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle. 12:491–500. 2013. View Article : Google Scholar : PubMed/NCBI
26	Aldea MD, Petrushev B, Soritau O, Tomuleasa CI, Berindan-Neagoe I, Filip AG, Chereches G, Cenariu M, Craciun L, Tatomir C, et al: Metformin plus sorafenib highly impacts temozolomide resistant glioblastoma stem-like cells. J BUON. 19:502–511. 2014.PubMed/NCBI
27	Chen G, Nicula D, Renko K and Derwahl M: Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncol Rep. 33:1994–2000. 2015.PubMed/NCBI
28	Zhang K and Waxman DJ: Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model. Mol Cancer Ther. 12:787–798. 2013. View Article : Google Scholar : PubMed/NCBI
29	Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, et al: Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res. 14:7272–7283. 2008. View Article : Google Scholar : PubMed/NCBI
30	Fenton BM and Paoni SF: The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature. Cancer Res. 67:9921–9928. 2007. View Article : Google Scholar : PubMed/NCBI
31	Wang F, Mi YJ, Chen XG, Wu XP, Liu Z, Chen SP, Liang YJ, Cheng C, To KK and Fu LW: Axitinib targeted cancer stemlike cells to enhance efficacy of chemotherapeutic drugs via inhibiting the drug transport function of ABCG2. Mol Med. 18:887–898. 2012.PubMed/NCBI
32	Lu L, Saha D, Martuza RL, Rabkin SD and Wakimoto H: Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma. J Neurooncol. 121:91–100. 2015. View Article : Google Scholar
33	McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU and Forsyth PA: In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells. Neuro Oncol. 17:1086–1094. 2015. View Article : Google Scholar : PubMed/NCBI
34	Gomez-Casal R, Bhattacharya C, Ganesh N, Bailey L, Basse P, Gibson M, Epperly M and Levina V: Non-small cell lung cancer cells survived ionizing radiation treatment display cancer stem cell and epithelial-mesenchymal transition phenotypes. Mol Cancer. 12:942013. View Article : Google Scholar : PubMed/NCBI
35	Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG and Wicha MS: Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci USA. 109:2784–2789. 2012. View Article : Google Scholar : PubMed/NCBI
36	Piao Y, Liang J, Holmes L, Zurita AJ, Henry V, Heymach JV and de Groot JF: Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype. Neuro Oncol. 14:1379–1392. 2012. View Article : Google Scholar : PubMed/NCBI
37	Chinchar E, Makey KL, Gibson J, Chen F, Cole SA, Megason GC, Vijayakumar S, Miele L and Gu JW: Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells. Vasc Cell. 6:122014. View Article : Google Scholar : PubMed/NCBI
38	Clery JP, Gomez E, Sharma M, Khemani A, Sharma C, Punzalan R, Navel M, Amezcua N, Jani J and Sharma J: Optimal drug concentration screening and evaluation in cancer stem cells & 3D tumor stem cell cultures drug response assays in association with clinical efficacy for pancreatic cancer stem cell. Cancer Res. 73:55452013. View Article : Google Scholar
39	Sharma J, DiMaggio CM, Taw N, Majdoub M, Liles N, Velazquez G, Amezcua N, Sharma C and Sharma M: Human liver cancer stem cells as a potential target for novel drug therapy and drug discovery. The American Society for Cell Biology 2009 Annual Meeting Regular; Abstracts, no. B48. 2009
40	Cleary JP, Raman D, Punzalan RR, et al: Targeting cancer stem cells as potential new therapy for pancreatic cancer. Cancer Res. 72:44082012. View Article : Google Scholar
41	Sharma CVR, Passarini JD, Majdoub MW, DiMaggio CM, Sobhy OM, Punzalan RR, Sharma MRV, Harris-White ME, Warden MW, Sharma SP and Sharma JP: Human triple-negative breast cancer stem cells utilized for drug discovery therapeutics for triple-negative breast cancer patients. Cancer Res. 70:33192010. View Article : Google Scholar
42	Passarini J, Cleary JP, Kumar P, Newton T, Sharma M, Sharma C, Panunzalan RR, Gill P, Sharma S, Srivastava R, Shankar S and Sharma JP: Screening potential drug candidates for treatment of glioblastoma patients utilizing an in-vivo mouse/rat model system. Cancer Res. 71:33062011. View Article : Google Scholar
43	Ebert T, Bander NH, Finstad CL, Ramsawak RD and Old LJ: Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer Res. 50:5531–5536. 1990.PubMed/NCBI
44	Breslin S and O'Driscoll L: Receptor tyrosine kinase targeting in multicellular spheroids. Methods Mol Biol. 1233:161–168. 2015. View Article : Google Scholar
45	Foty R: A simple hanging drop cell culture protocol for generation of 3D spheroids. J Vis Exp. 51:27202011.PubMed/NCBI
46	Schneider CA, Rasband WS and Eliceiri KW: NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9:671–675. 2012. View Article : Google Scholar : PubMed/NCBI
47	Abramoff MD, Magalhaes PJ and Ram SJ: Image processing with ImageJ. Biophotonics Int. 11:36–42. 2004.
48	Nakayama GR, Caton MC, Nova MP and Parandoosh Z: Assessment of the Alamar Blue assay for cellular growth and viability in vitro. J Immunol Methods. 204:205–208. 1997. View Article : Google Scholar : PubMed/NCBI
49	Triglia D, Sherard Braa S, Yonan C and Naughton GK: Cytotoxicity testing using neutral red and MTT assays on a three-dimensional human skin substrate. Toxicol In Vitro. 5:573–578. 1991. View Article : Google Scholar : PubMed/NCBI
50	Vistica DT, Skehan P, Scudiero D, Monks A, Pittman A and Boyd MR: Tetrazolium-based assays for cellular viability: A critical examination of selected parameters affecting formazan production. Cancer Res. 51:2515–2520. 1991.PubMed/NCBI
51	Machesky LM: Lamellipodia and filopodia in metastasis and invasion. FEBS Lett. 582:2102–2111. 2008. View Article : Google Scholar : PubMed/NCBI
52	Négrier S and Raymond E: Antiangiogenic treatments and mechanisms of action in renal cell carcinoma. Invest New Drugs. 30:1791–1801. 2012. View Article : Google Scholar
53	O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, et al: SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 101:3597–3605. 2003. View Article : Google Scholar : PubMed/NCBI
54	Wiernik PH: FLT3 inhibitors for the treatment of acute myeloid leukemia. Clin Adv Hematol Oncol. 8:429–436. 4442010.PubMed/NCBI
55	Karaman MW, Herrgard S, Treiber DK, Gallant P, Atteridge CE, Campbell BT, Chan KW, Ciceri P, Davis MI, Edeen PT, et al: A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26:127–132. 2008. View Article : Google Scholar : PubMed/NCBI
56	Kitagawa D, Yokota K, Gouda M, Narumi Y, Ohmoto H, Nishiwaki E, Akita K and Kirii Y: Activity-based kinase profiling of approved tyrosine kinase inhibitors. Genes Cells. 18:110–122. 2013. View Article : Google Scholar : PubMed/NCBI
57	Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, et al: In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmaco-dynamic relationship. Clin Cancer Res. 9:327–337. 2003.PubMed/NCBI
58	Potapova O, Laird AD, Nannini MA, Barone A, Li G, Moss KG, Cherrington JM and Mendel DB: Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. Mol Cancer Ther. 5:1280–1289. 2006. View Article : Google Scholar : PubMed/NCBI
59	Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H, Honeywell RJ, Rudek MA, Beerepoot LV, Musters RJ, Jansen G, et al: Lysosomal sequestration of sunitinib: A novel mechanism of drug resistance. Clin Cancer Res. 17:7337–7346. 2011. View Article : Google Scholar : PubMed/NCBI
60	Gotink KJ, Broxterman HJ, Honeywell RJ, Dekker H, de Haas RR, Miles KM, Adelaiye R, Griffioen AW, Peters GJ, Pili R, et al: Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience. 1:844–853. 2014. View Article : Google Scholar
61	Ma J, Chen CS, Blute T and Waxman DJ: Antiangiogenesis enhances intratumoral drug retention. Cancer Res. 71:2675–2685. 2011. View Article : Google Scholar : PubMed/NCBI
62	Al Hazzouri A, Vaziri SA, Lynch M, Schwartz B, Rini BI, Bukowski R and Ganapathy R: Anti-proliferative effects of sorafenib in clear cell renal cell carcinoma (CCRCC) cell lines: Relationship to von Hippel-Lindau protein (pVHL) expression and hypoxia. J Clin Oncol. 24:46012006.
63	Juengel E, Kim D, Makarević J, Reiter M, Tsaur I, Bartsch G, Haferkamp A and Blaheta RA: Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. J Cell Mol Med. 19:430–441. 2015. View Article : Google Scholar :